Patent ID: 7862820
Filing Date: 2011-01-04
Classification: A61K,A61P,C07K,C12N,C12Y

Abstract:
1. A method of treating a subject with a bleeding disease or disorder comprising administering to the subject a pharmaceutically acceptable amount of a monomer-dimer hybrid protein, which comprises a first polypeptide and a second polypeptide, wherein said first polypeptide comprises (i) a clotting factor selected from the group consisting of Factor VII, Factor VIIa, Factor VIII, Factor VIIIa, Factor IX, Factor IXa, von Willebrand factor, Factor X, and Factor Xa, and (ii) an immunoglobulin constant region or portion thereof comprising a neonatal Fc Receptor binding site, and said second polypeptide consists of an immunoglobulin constant region or portion thereof comprising a neonatal Fc Receptor binding site without the clotting factor of said first polypeptide, and wherein said first polypeptide and said second polypeptide are linked.